objective In 2004, Sierra Leone adopted artesunate plus amodiaquine as first-line antimalarial treatment. We evaluated the efficacy of this combination in Kailahun, where a previous study had shown 70.2% efficacy of amodiaquine in monotherapy.
Introduction
In 2002-2003, a multicentric antimalarial efficacy study was carried out in Sierra Leone by Checchi and colleagues (2005) . This study demonstrated the low overall efficacy of both first-and second-line antimalarial drugs, chloroquine (CQ) and sulfadoxine-pyrimethamine (SP). The efficacy of amodiaquine (AQ), the third monotherapy tested, varied within the country, ranging from 94.6% to 70.2%. The lowest efficacy was reported in Kailahun (Checchi et al. 2005) .
In 2004, the Ministry of Health and Sanitation, following WHO recommendations (WHO/RBM 2003), adopted artesunate plus AQ (AS + AQ) as first-line antimalarial treatment and artemether plus lumefantrine (CoartemÒ) as second-line. AS + AQ was expected to be highly efficacious (Adjuik et al. 2002) and well tolerated (Adjuik et al. 2004) . However, the high efficacy of AS + AQ, that would expect with the introduction of a new treatment, could not be guaranteed in Kailahun, given the relatively low efficacy of monotherapy AQ in the previous year. In 2004 we assessed, therefore, the in vivo efficacy of AS + AQ in Kailahun. We report here the study results.
Methods and materials
The study took place at the outpatient department of Médecins Sans Frontières (MSF) hospital in Kailahun town (Figure 1 ). This structure also hosted the previous study and we followed the same protocol (Checchi et al. 2005) , as summarized below.
Eligibility for inclusion and clinical and parasitological evaluation were according to WHO recommendations (WHO 1996) . Children aged 6-59 months with confirmed uncomplicated Plasmodium falciparum malaria and meeting inclusion criteria were enrolled, treated on site with 3-day artesunate, 4 mg/kg/day (ArsumaxÒ, Sanofi Winthrop AMO, Gentilly, France), and amodiaquine, 10 mg/ kg/day (CamoquinÒ, Pfizer, Dakar, Senegal), and were followed-up for a period of 28 days. Based on available data on the gain in efficacy when AS is added to AQ, and the known failure of AQ in Kailahun (29.8%), 15% failure was hypothesized for AS + AQ. A size of 126 children was estimated; assuming a 95% significance level (precision of ± 7.5%); taking in account 20% possible withdrawals; and, 20% expected reinfections occurring during follow-up.
Both thick and thin blood smears were taken from enrolled patients on day 0, 2, 3, 7, 14, 21, 28 and any other day if needed. Microscopic examination was done under 100· oil immersion magnification. A physician examined the child's clinical condition during the entire follow-up period.
All therapeutic failures received a rescue treatment consisting of oral quinine hydrochloride, 8 mg/kg every 8 h for 7 days, or artemether intramuscular, 3.2 mg/kg loading dose, followed by 1.6 mg/kg/day for at least 3 days, when oral intake was not possible. All children received antihelmintic (mebendazole 250 mg or albendazole 400 mg). Children with initial haemoglobin below 10 g/dl received ferrous sulphate 30 mg/kg/day for 2 months and folic acid 5 mg/day, starting from day 7 for 1 month.
Gametocyte carriage was measured on days 0, 3, 7, 14, 21 and 28. Haemoglobin levels were measured on day 0, 14 and 28 with the Lovibond undiluted colorimetric technique (Lovibond, Assistant Co. Sondheim Rhon, Germany). Children were considered non anaemic when haemoglobin was ‡ 11.0 g/dl, mildly anaemic when haemoglobin was ‡8 and <11.0 g/dl, and moderately anaemic when haemoglobin was ‡5 and <8.0 g/dl.
PCR genotyping, using msp-1 and msp-2 markers, was applied to distinguish true recrudescences, due to treatment failure, from episodes of reinfection (WHO 2002) . Recrudescence was identified when pre-and post-treatment sample alleles were the same; re-infection was identified when pre-and post-treatment sample alleles were distinct; and mixed recrudescence and re-infection when similar pre-and post-treatment samples alleles were found, but with additional distinct alleles identified. Analysis was carried out at the Laboratory of Parasitology and Mycology of Avicenne Hospital, Bobigny (France), using a published method (Ranford-Cartwright et al. 1997; Snounou et al. 1999) .
Data were double entered and validated using EpiData (The EpiData Association, Odense, Denmark) and analysed using Stata 8.0 (College Station, TX). Total number of failures (early treatment failure + late clinical failure + late parasitological failure [ETF + LCF + LPF]) were calculated over the total number of analysable outcomes, and expressed as a percentage with associated 95% confidence intervals. During the 28-day follow-up, treatment failures, which were confirmed to be recrudescence or mixed recrudescence/reinfection by PCR genotyping, were classified as true failures, while pure reinfections were reclassified as adequate clinical and parasitological response (ACPR). Although the reclassification of reinfection as ACPR was no longer recommended (WHO 2003), we kept this method to compare our results with those of the previous multi-centric study (Checchi et al. 2005) . Patients for which the PCR result was inconclusive (indeterminate or no DNA isolated), secondary exclusions and patients lost to follow-up were excluded from the analysis.
The failure proportion on day 14 (without PCR adjustment) was also calculated. Haemoglobin levels on day 0 and day 28 were compared (McNemar's test).
The Ethics Committee of the Ministry of Health and Sanitation of Sierra Leone approved the study protocol.
Results
Between 14 July and 26 August 2004, of 172 children aged 6-59 months admitted to the clinic, 126 satisfied the inclusion criteria, and were enrolled in the study. The male/ female ratio was 0.75 (54/72). Other baseline characteristics are described in Table 1 . Three children, although able to drink or breast feed, did not complete the treatment because of repeated vomiting of the drugs; 10 children were also withdrawn because of a concomitant illness requiring hospitalization (n ¼ 8) or because of other Fever clearance on day 2 (<37.5°C) and parasite clearance on day 3 were 95.2% (119/125) and 94.2% (114/121) respectively. Haemoglobin recovery was assessed among the 87 children who attended for their day 28 visit. Among the 80 children anaemic on day 0 (71 mildly and 9 moderately anaemic), 27 (33.7%) were no longer anaemic on day 28 (P < 0.001), regardless of the therapeutic outcome; four children not anaemic on day 0 became moderately anaemic on day 28.
On the day of inclusion, 5.6% of children (7/126) were reported having gametocytes. The proportion increased to 11.6% (14/121) on day 7 and progressively decreased (Figure 2 ) until day 28 when none of the children were gametocytaemic.
Discussion
The results until day 14 were extremely promising. AS + AQ resulted in a high day 2 fever clearance and a high day 3 parasite clearance, which has been shown in previous studies (Staedke et al. 2004; Hamour et al. 2005) . No early treatment failures were reported and therapeutic efficacy on day 14 was also very high (98.2%). The day 28 efficacy (84.5%), nevertheless, confirmed expectations and fears, given the already low efficacy of the monotherapy AQ the previous year (Checchi et al. 2005) . These results questioned whether AS + AQ is suitable first-line treatment in Kailahun. Low efficacies of this combination have also been recently reported in Africa (Rwagacondo et al. 2004) and in Asia (Durrani et al. 2005) .
On one hand, AS + AQ would undoubtedly contribute to a general improvement of malaria case management, compared to the previous situation where malaria patients were treated with ineffective drugs. The day 28 failures were almost half of those that occurred with monotherapy AQ (15.5% vs. 29.2%) (Checchi et al. 2005) ; on day 28 no children were reported carrying gametocytes; and a considerable number reported improved haemoglobin level, even if this was probably the result of the combined effect of having recovered from malaria and the benefit of antihelmintic and supportive treatments. On the other hand, the day 28 efficacy was far from what we would expect from a newly introduced treatment, and the high reinfection rate suggested that this combination provided little prophylactic effect. The maintenance of the current efficacy over time needs to be monitored and we cannot exclude that an alternative treatment might be necessary in the near future in Kailahun. Alternatives, however, are few. Artemether plus lumefantrine (CoartemÒ), the current second-line treatment, is highly efficacious in Africa (Mutabingwa et al. 2005; Piola et al. 2005 ), but it is currently more expensive than AS + AQ. Little information is yet available about the long term effects of the large scale use of ACTs in Africa. It is hoped that, as in Thailand (Brockman et al. 2000) , the use of a drug in combination with an artemisinin slows the resistance process. The long-term positive results in Asia, though obtained in lower transmission settings, are encouraging. Further studies to monitor the efficacy of AS + AQ are necessary in Kailahun and in other regions of the country. mots clé s Plasmodium falciparum, thérapies de combinaison à l'artemisinine, artésunate, amodiaquine, efficacité in vivo, Sierra Leone Baja eficacia de la combinació n de artesunato con amodiaquina para el tratamiento de malaria por falciparum no complicada entre niñ os menores de 5 añ os en Kailahun, Sierra Leone objetivo: En el 2004, Sierra Leona adoptó el artesunato má s amodiaquina como primera línea de tratamiento para malaria. Evaluamos la eficacia de esta combinació n en Kailahun, en donde un estudio previo había demostrado una eficacia de la amodiaquina en monoterapia del 70.2%. mé todos: La metodología y la clasificació n de los resultados cumplían con las directrices de la OMS. Los niñ os entre 6 y 59 meses, con malaria no complicada, fueron seguidos durante 28 días. Se utilizó el genotipaje mediante PCR para distinguir entre reinfecció n y recrudecimiento. Las reinfecciones fueron clasificadas como curados.
resultados: De 172 niñ os derivados a la clínica del estudio, 126 satisfacían los criterios de inclusió n y entraron en el estudio. No se reportaron fallas terapéuticas tempranas. La eficacia a los 14 días fue del 98.2% (95% CI: 93.8-99.8). De 65 parasitemias recurrentes analizadas por PCR, 17 eran recrudescencias. La eficacia a día 28, ajustada por PCR, fue del 84.5% (95% CI: 76.4-90.7). Todas los fallos verdaderos ocurrieron durante los ú ltimos 8 días de seguimiento. De 110 niñ os que terminaron los 28 días de seguimiento, 54 (49.1%) experimentaron una infecció n nueva.
conclusió n: La eficacia de esta combinació n fue decepcionante. La alta tasa de reinfecció n sugiere poco efecto profilá ctico. En Kailahun se requiere una combinació n má s eficaz, aunque actualmente existen pocas alternativas disponibles. La eficacia de AS + AQ requiere monitorizació n tanto en Kailahun como en otras regiones de Sierra Leona.
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